Endoscopic Ultrasound‐Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment
Cancer Reports · 2025
DOI: 10.1002/cnr2.70414 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Reports, 2025. Verfasst von Yuichi Takano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Liver Neoplasms, Biomarkers, Tumor, Endoscopic Ultrasound-Guided Fine Needle Aspiration. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Since biomarker expression may differ between primary and metastatic lesions, biopsy of metastatic sites is recommended whenever feasible. The liver is a common metastatic site for breast cancer, and percutaneous biopsy has traditionally been the standard approach. Recently, endoscopic ultrasound‐guided tissue acquisition (EUS‐TA) has emerged as an alternative method for sampling focal liver lesions. However, the utility of EUS‐TA in assessing breast cancer biomarkers remains unclear.
Aim
To evaluate the diagnostic performance of EUS‐TA, including its ability to assess biomarkers in liver metastases from breast cancer.
Methods
This single‐center, retrospective observational study included patients who underwent EUS‐TA for breast cancer liver metastases between 2016 and 2023. Clinical characteristics and specimen adequacy were analyzed. A pathologist classified the obtained tissue samples into four categories: (A) insufficient for diagnosis, (B) diagnosis possible only at the cytology level, (C) histological evaluation possible, but additional immunostaining for biomarkers not feasible, and (D) histological evaluation and additional immunostaining for biomarkers feasible.
Results
Fifteen cases were included, with a median patient age of 68 years (all female). The median liver lesion size was 20 mm (range: 8–50 mm). The lesions were located in the left lobe in 12 cases and the right lobe in 3 cases. A 22G needle was used in 14 cases, while a 25G needle was used in 1 case. Specimen adequacy was classified as follows: category A in 1 case (6.6%), B in 2 cases (13.3%), C in 0 cases (0%), and D in 12 cases (80%). Biomarker evaluation was feasible in the majority of cases. No procedure‐related adverse events were observed.
Conclusion
EUS‐TA is a valuable method for obtaining tissue samples from breast cancer liver metastases, enabling biomarker assessment in most cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
ORCID-Profile: Yuichi Takano, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Fumitaka Niiya, Naotaka Maruoka, Tatsuya Yamagami, Masatsugu Nagahama
Zitieren
APA
Takano, Y., Tamai, N., Yamawaki, M., Noda, J., Azami, T., Niiya, F., Maruoka, N., Yamagami, T., & Nagahama, M. (2025). Endoscopic Ultrasound‐Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment. Cancer Reports. https://doi.org/10.1002/cnr2.70414
Vancouver
Takano Y, Tamai N, Yamawaki M, Noda J, Azami T, Niiya F, et al. Endoscopic Ultrasound‐Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment. Cancer Reports. 2025. doi:10.1002/cnr2.70414
BibTeX
@article{Takano2025,
author = {Takano, Yuichi and Tamai, Naoki and Yamawaki, Masataka and Noda, Jun and Azami, Tetsushi and Niiya, Fumitaka and Maruoka, Naotaka and Yamagami, Tatsuya and Nagahama, Masatsugu},
title = {Endoscopic Ultrasound‐Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70414}
}
EUVIMED